Related Experiment Videos
[Recurrent agranulocytosis after taking calcium dobesilate]
W Kulessa1, E W Becker, P A Berg
1Innere und Geriatrische Abteilung, Jakobi-Krankenhaus Rheine.
Deutsche Medizinische Wochenschrift (1946)
|March 6, 1992
Summary
Calcium dobesilate, a medication for vascular disorders, has been linked to a rare but serious side effect: agranulocytosis. This case study highlights the potential for drug-induced immune responses, emphasizing careful patient history and diagnostic testing.
Area of Science:
- Clinical Immunology
- Hematology
- Pharmacology
Background:
- Agranulocytosis is a severe reduction in white blood cells, increasing infection risk.
- Drug-induced agranulocytosis is a known but often underdiagnosed adverse effect.
- Calcium dobesilate is commonly used for chronic venous insufficiency and diabetic retinopathy.
Observation:
- A 64-year-old woman presented with recurrent pyoderma, fever, and agranulocytosis.
- Initial treatment with antibiotics (cefotaxime, ofloxacin) led to temporary recovery.
- Patient history revealed prior calcium dobesilate use before each agranulocytosis episode.
Findings:
- Lymphocyte transformation tests confirmed a specific immune response to calcium dobesilate.
- This suggests an allergic mechanism underlying the drug-induced agranulocytosis.
- This is the first reported case of agranulocytosis linked to calcium dobesilate.
Implications:
- Highlights the importance of thorough drug history in diagnosing agranulocytosis.
- Suggests calcium dobesilate as a potential cause of drug-induced agranulocytosis.
- Warrants further investigation into the immunogenic potential of calcium dobesilate.